Journal of Clinical Psychopharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Myocarditis After Clozapine Initiation and mRNA SARS-CoV-2 Vaccination
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Letters to the Editors – Case Reports Source Type: research

A Withdrawal Syndrome After a Switch of Phenibut to Another γ-Aminobutyric Acid Agonist
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Letter to the Editors Source Type: research

A Systematic Review of Clinical Trials on Lumateperone and Its Effects on Body Weight
Conclusions Lumateperone displays minimal to no weight gain among participants in the studies reviewed. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Review Articles Source Type: research

Placebo Effect in Randomized Trials of Major Depressive Disorder With Psychotic Features: A Systematic Review and Descriptive Meta-Analysis
Conclusions As expected, response rates to placebo pills in RCTs for MDD-Psy increased markedly from the 1980s to the 2000s. Methodological issues in the design and conduct of more recent RCTs may have contributed to the high placebo response. However, one needs to consider this placebo response rate when interpreting the result of recent trials of MDD-Psy, which typically have not included a “pure” placebo condition. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Review Articles Source Type: research

Effectiveness and Tolerability of Lurasidone for Bipolar Types I and II and Other Specified Bipolar Depression: A 12-Week Observational Study
Background There are few guidelines on the management of depressive episodes in patients with bipolar type II (BDII) and related disorders (other specified bipolar and related disorders [OSBD]). Lurasidone is a potential option for treating depressive episodes in BDII/OSBD. This retrospective chart review study aimed to examine the effectiveness and tolerability of lurasidone for use in patients with bipolar depression. Methods We reviewed 66 consecutive outpatients with bipolar depression who were prescribed lurasidone between June 2020 and January 2021 and examined 12-week outcomes. Fourteen patients were diag...
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Brief Reports Source Type: research

Paliperidone-Associated Sialorrhea: A Case Report With Review of Current Literature
Conclusions Clinicians should be aware of the potential for paliperidone and other nonclozapine second-generation antipsychotics to be associated with sialorrhea, especially given the increased frequency of their use for a variety of psychiatric disorders. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Brief Reports Source Type: research

Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics
Conclusions Our results demonstrated a comparative risk of EPS across all 3 antipsychotic classes. Risperidone was associated with more EPS compared with other medications. A higher threshold for the “maximum dose” of paliperidone could be considered and higher doses used with the same cautions as low-average doses. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Brief Reports Source Type: research

Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment: A Retrospective Pilot Study
Purpose/Background Pharmacokinetics may be of relevance for the risk of clozapine discontinuation. We compared metabolite profiles, accounting for smoking habits, in patients switching versus maintaining clozapine treatment at therapeutic concentrations. Methods/Procedures Adult patients with clozapine serum levels above 1070 nmol/L (350 ng/mL) were retrospectively included from a Norwegian therapeutic drug monitoring service during 2018–2020. Inclusion criteria were (1) known smoking habits, (2) blood sample drawn within 10 to 30 hours after last clozapine intake, and (3) detectable levels of N-desmethylcloza...
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Brief Reports Source Type: research

Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder: A Review of the Evidence, Neurobiological Plausibility, and Clinical Significance
Conclusions There is strong neurobiological plausibility for the hypothesis that chronic SSRI use dampens response to MDMA-assisted therapy, although current knowledge in the field is limited and primarily relates to acute pharmacodynamic interactions. Our commentary highlights the urgent need for future work dedicated to addressing this important clinical topic. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Brief Reports Source Type: research

Case Reports: Exposure to SARS-CoV-2, Acute Kidney Injury, and Lithium Toxicity
This study discussed these cases in context of previous case reports and relevant literature pertaining to lithium and exposure to SARS-CoV-2. Findings Infection with SARS-CoV-2 along with symptoms of COVID-19 and mental state changes in three individuals were temporally associated with lithium levels in the toxic range. Implications Exposure to SARS-CoV-2 or symptoms suggestive of COVID-19 should result in increased clinical monitoring of individuals taking lithium. Those taking lithium and providers are advised to have a low clinical threshold for requesting lithium levels and kidney function estimates for ...
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Brief Reports Source Type: research

The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis
Purpose/Background Tardive dyskinesia (TD) is a hyperkinetic movement disorder caused by exposure to dopamine-receptor blockers. Data on TD burden in Israel are scarce. This analysis assesses the clinical and economic burden of TD in Israeli patients. Methods/Procedures This retrospective analysis used a national health plan database (Maccabi Healthcare Services), representing 25% of the Israeli population. The study included adults alive at index date with an International Classification of Diseases, Ninth Revision, Clinical Modification TD diagnosis before 2018 and more than or equal to 1-year enrollment befor...
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Original Contributions Source Type: research

The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder
Conclusions Brexpiprazole might be effective in ADHD adults who are nonresponders to 2 or more stimulants. Future trials in treatment-resistant ADHD should use a 1:1 randomization and use a measure of ADHD symptoms that includes emotional dysregulation. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Original Contributions Source Type: research

Drug-Associated Liver Injury Related to Antipsychotics: Exploratory Analysis of Pharmacovigilance Data
Conclusions Several common antipsychotics are associated with hepatotoxicity, partly also with severe hepatotoxicity. Our data do not allow to account for patient-related risk factors for drug-associated liver injury. This should be addressed in further studies. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Original Contributions Source Type: research

Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials
Conclusions These are the first large-scale studies to demonstrate the efficacy and safety profiles of 200 mg/d and 400 mg/d centanafadine in adults with ADHD. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Original Contributions Source Type: research

Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2022 Category: Psychiatry Tags: Guest Editorial Source Type: research